Literature DB >> 20797634

Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif.

Ivan Matic1, Joost Schimmel, Ivo A Hendriks, Maria A van Santen, Frans van de Rijke, Hans van Dam, Florian Gnad, Matthias Mann, Alfred C O Vertegaal.   

Abstract

Reversible protein modification by small ubiquitin-like modifiers (SUMOs) is critical for eukaryotic life. Mass spectrometry-based proteomics has proven effective at identifying hundreds of potential SUMO target proteins. However, direct identification of SUMO acceptor lysines in complex samples by mass spectrometry is still very challenging. We have developed a generic method for the identification of SUMO acceptor lysines in target proteins. We have identified 103 SUMO-2 acceptor lysines in endogenous target proteins. Of these acceptor lysines, 76 are situated in the SUMOylation consensus site [VILMFPC]KxE. Interestingly, eight sites fit the inverted SUMOylation consensus motif [ED]xK[VILFP]. In addition, we found direct mass spectrometric evidence for crosstalk between SUMOylation and phosphorylation with a preferred spacer between the SUMOylated lysine and the phosphorylated serine of four residues. In 16 proteins we identified a hydrophobic cluster SUMOylation motif (HCSM). SUMO conjugation of RanGAP1 and ZBTB1 via HCSMs is remarkably efficient. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20797634     DOI: 10.1016/j.molcel.2010.07.026

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  143 in total

Review 1.  Human pathogens and the host cell SUMOylation system.

Authors:  Peter Wimmer; Sabrina Schreiner; Thomas Dobner
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 2.  Trojan horse strategies used by pathogens to influence the small ubiquitin-like modifier (SUMO) system of host eukaryotic cells.

Authors:  Miklós Békés; Marcin Drag
Journal:  J Innate Immun       Date:  2012-01-03       Impact factor: 7.349

Review 3.  POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function.

Authors:  Sung-Uk Lee; Takahiro Maeda
Journal:  Immunol Rev       Date:  2012-05       Impact factor: 12.988

4.  Small ubiquitin-like modifier (SUMO) modification of E1 Cys domain inhibits E1 Cys domain enzymatic activity.

Authors:  Khue Truong; Terry D Lee; Yuan Chen
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

5.  A novel proteomics approach to identify SUMOylated proteins and their modification sites in human cells.

Authors:  Frederic Galisson; Louiza Mahrouche; Mathieu Courcelles; Eric Bonneil; Sylvain Meloche; Mounira K Chelbi-Alix; Pierre Thibault
Journal:  Mol Cell Proteomics       Date:  2010-11-22       Impact factor: 5.911

6.  RpL22e, but not RpL22e-like-PA, is SUMOylated and localizes to the nucleoplasm of Drosophila meiotic spermatocytes.

Authors:  Michael G Kearse; Jill A Ireland; Smrithi M Prem; Alex S Chen; Vassie C Ware
Journal:  Nucleus       Date:  2013-06-06       Impact factor: 4.197

Review 7.  The SUMO system: a master organizer of nuclear protein assemblies.

Authors:  Nithya Raman; Arnab Nayak; Stefan Muller
Journal:  Chromosoma       Date:  2013-08-06       Impact factor: 4.316

8.  Targeted identification of SUMOylation sites in human proteins using affinity enrichment and paralog-specific reporter ions.

Authors:  Frederic Lamoliatte; Eric Bonneil; Chantal Durette; Olivier Caron-Lizotte; Dirk Wildemann; Johannes Zerweck; Holger Wenshuk; Pierre Thibault
Journal:  Mol Cell Proteomics       Date:  2013-06-07       Impact factor: 5.911

Review 9.  SUMO rules: regulatory concepts and their implication in neurologic functions.

Authors:  Mathias Droescher; Viduth K Chaugule; Andrea Pichler
Journal:  Neuromolecular Med       Date:  2013-08-30       Impact factor: 3.843

Review 10.  Roles of Sumoylation in mRNA Processing and Metabolism.

Authors:  Patricia Richard; Vasupradha Vethantham; James L Manley
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.